| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT06968845 A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · Rein Therapeutics |
Trial sites expanded: 30 -> 36 locations |
| 2026-08-13 | NCT01915511 Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry · Duke University |
Trial sites expanded: 44 -> 47 locations |
| 2026-08-13 | NCT07743996 Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary… · Boehringer Ingelheim |
Recruitment opened |
| 2026-08-12 | NCT05988463 Dose-Escalation Study of Artesunate Patients With IPF · Joseph C. Wu |
date change Primary completion pushed: 2027-11-01 -> 2028-11-01 |
| 2026-08-11 | NCT07284459 Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With… · Contineum Therapeutics |
Trial sites expanded: 60 -> 64 locations |
| 2026-08-11 | NCT07194382 AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02… · Avalyn Pharma Inc. |
Trial sites expanded: 3 -> 24 locations |
| 2026-08-09 | NCT07329959 CAR-DC for End-Stage IPF · Second Affiliated Hospital, School of Medicine, Zhejiang University |
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine |
| 2026-08-09 | NCT05899556 Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis… · Power Life Sciences Inc. |
overall status: Not Yet Recruiting → Unknown |
| 2026-08-09 | NCT04304898 An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using… · Erasmus Medical Center |
overall status: Recruiting → Unknown |
| 2026-08-08 | NCT06951217 An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) · Avalyn Pharma Inc. |
Trial sites expanded: 54 -> 68 locations |
| 2026-08-04 | NCT07036029 NAL ER IPF Respiratory Function and Safety Study · Trevi Therapeutics |
Trial completed |
| 2026-08-04 | NCT07036029 NAL ER IPF Respiratory Function and Safety Study · Trevi Therapeutics |
Enrollment reduced: 10 -> 9 participants |
| 2026-08-04 | NCT07284459 Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With… · Contineum Therapeutics |
Trial sites expanded: 57 -> 60 locations |
| 2026-08-02 | NCT06304207 Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease · MGH Institute of Health Professions |
overall status: Recruiting → Unknown |
| 2026-08-01 | NCT06230822 Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary… · Wuhan Optics Valley Vcanbiopharma Co., Ltd. |
Trial completed |
| 2026-08-01 | NCT06230822 Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary… · Wuhan Optics Valley Vcanbiopharma Co., Ltd. |
date change Primary completion pushed: 2025-01 -> 2025-03-13 |
| 2026-08-01 | NCT06230822 Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary… · Wuhan Optics Valley Vcanbiopharma Co., Ltd. |
date change Completion moved earlier: 2026-12 -> 2025-08-01 |
| 2026-07-29 | NCT04905693 Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease · United Therapeutics |
date change Primary completion pushed: 2026-06 -> 2029-12 |
| 2026-07-29 | NCT04905693 Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease · United Therapeutics |
date change Completion pushed: 2026-06 -> 2029-12 |
| 2026-07-24 | NCT06968845 A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · Rein Therapeutics |
Trial sites expanded: 21 -> 30 locations |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-08-12 | NCT07761377 Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest… | Taichung Veterans General Hospital NEW | |
| 2026-07-22 | NCT07719023 A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary… | Shanghai Ark Biopharmaceutical Co., Ltd. NEW | Phase 3 |
| 2026-07-16 | NCT07707245 Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of… | Fondazione Don Carlo Gnocchi ETS NEW | |
| 2026-07-07 | NCT07687459 Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic… | InSilico Medicine Hong Kong Limited NEW | Phase 3 |
| 2026-07-07 | NCT07686562 Artificial Intelligence (AI) Detection of Incidental Interstitial Opacity on Chest… | Chung-Ang University Hospital NEW | |
| 2026-07-06 | NCT07683728 A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in… | Zuojun Xu NEW | |
| 2026-07-02 | NCT07682337 Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects | SCBIO Inc. NEW | Phase 1 |
| 2026-06-29 | NCT07673237 Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease… | University of California, San Francisco NEW | |
| 2026-06-17 | NCT07652658 A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. | AstraZeneca NEW | Phase 2 |
| 2026-05-29 | NCT07613216 A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects… | Cosmos Rx, Inc NEW |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07570888 | This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate… | University of British Columbia | Not Yet Recruiting |
| Phase 3 | |||
| NCT04965298 | Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole | Norfolk and Norwich University Hospitals NHS Foundation Trust | Recruiting |
| NCT05674994 | Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic… | Fondation Hôpital Saint-Joseph | Recruiting |
| NCT07464912 | A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension… | Beijing Tide Pharmaceutical Co., Ltd | Recruiting |
| NCT07299695 | Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic… | Argyrios Tzouvelekis | Recruiting |
| NCT07082842 | Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | Sunshine Lake Pharma Co., Ltd. | Recruiting |
| NCT07671911 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine… | Trevi Therapeutics | Recruiting |
| NCT05943535 | Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive… | United Therapeutics | Recruiting |
| NCT07284602 | Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to… | PureTech | Recruiting |
| NCT06238622 | A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary… | Boehringer Ingelheim | Recruiting |
| NCT07201922 | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People… | Boehringer Ingelheim | Recruiting |
| NCT06003426 | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants… | Bristol-Myers Squibb | Active, Not Recruiting |
| NCT07503587 | Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary… | Haisco Pharmaceutical Group Co., Ltd. | Not Yet Recruiting |
| NCT07519070 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate… | Haisco Pharmaceutical Group Co., Ltd. | Not Yet Recruiting |
| NCT07520110 | Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis | University of Massachusetts, Worcester | Not Yet Recruiting |
| NCT06025578 | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants… | Bristol-Myers Squibb | Active, Not Recruiting |
| NCT07687459 | Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic… | InSilico Medicine Hong Kong Limited | Not Yet Recruiting |
| NCT07719023 | A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary… | Shanghai Ark Biopharmaceutical Co., Ltd. | Not Yet Recruiting |
| NCT04905693 | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease | United Therapeutics | Enrolling by Invitation |
| NCT07441408 | Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in… | Bristol-Myers Squibb | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT06125327 | SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis… | Guangzhou JOYO Pharma Co., Ltd | Recruiting |
| NCT04948203 | Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of… | University of Chicago | Active, Not Recruiting |
| Phase 2 | |||
| NCT06189820 | Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases | Erasme University Hospital | Recruiting |
| NCT06567717 | Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis | Cedars-Sinai Medical Center | Recruiting |
| NCT05975983 | Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary… | InSilico Medicine Hong Kong Limited | Recruiting |